| Primary |
| Chemotherapy |
20.9% |
| Hyperuricaemia |
12.8% |
| Osteoporosis |
10.5% |
| Acute Myeloid Leukaemia |
7.0% |
| Back Pain |
5.8% |
| Prophylactic |
5.8% |
| Prophylaxis |
5.8% |
| B-cell Lymphoma Stage Iv |
4.7% |
| Lymphoma |
4.7% |
| Tumour Lysis Syndrome |
4.7% |
| Blood Uric Acid Increased |
2.3% |
| Disseminated Intravascular Coagulation |
2.3% |
| Multiple Myeloma |
2.3% |
| Sedation |
2.3% |
| Tumor Lysis Syndrome |
2.3% |
| Acute Leukaemia |
1.2% |
| Acute Lymphoblastic Leukemia |
1.2% |
| Acute Lymphocytic Leukaemia |
1.2% |
| Blood Pressure Decreased |
1.2% |
| Blood Uric Acid |
1.2% |
|
| Antibody Test Abnormal |
11.4% |
| Death |
11.4% |
| Hepatic Function Abnormal |
8.6% |
| Methaemoglobinaemia |
8.6% |
| Cardiac Arrest |
5.7% |
| Disease Progression |
5.7% |
| Dyspnoea |
5.7% |
| Haemolytic Anaemia |
5.7% |
| White Blood Cell Count Decreased |
5.7% |
| Cerebral Haemorrhage |
2.9% |
| Dialysis |
2.9% |
| General Physical Health Deterioration |
2.9% |
| Hepatotoxicity |
2.9% |
| Hypoxia |
2.9% |
| Leukopenia |
2.9% |
| Neutrophil Count Increased |
2.9% |
| Pancreatitis Acute |
2.9% |
| Pulmonary Alveolar Haemorrhage |
2.9% |
| Pyrexia |
2.9% |
| Refusal Of Treatment By Patient |
2.9% |
|
| Secondary |
| Product Used For Unknown Indication |
20.2% |
| Drug Use For Unknown Indication |
10.5% |
| Mantle Cell Lymphoma |
9.7% |
| Acute Myeloid Leukaemia |
7.5% |
| Burkitt's Lymphoma |
6.7% |
| Leukaemic Infiltration Brain |
6.7% |
| Premedication |
4.1% |
| Bone Pain |
3.7% |
| Chemotherapy |
3.7% |
| Prophylaxis |
3.4% |
| Leiomyosarcoma |
3.0% |
| Prevention |
3.0% |
| Acute Leukaemia |
2.6% |
| Back Pain |
2.2% |
| Gestational Trophoblastic Tumour |
2.2% |
| Hyperuricaemia |
2.2% |
| Leukaemia Recurrent |
2.2% |
| Tumour Lysis Syndrome |
2.2% |
| Acute Lymphocytic Leukaemia |
1.9% |
| Chronic Lymphocytic Leukaemia |
1.9% |
|
| Tumour Lysis Syndrome |
16.1% |
| Pancreatitis Acute |
9.7% |
| Cardiac Arrest |
6.5% |
| Death |
6.5% |
| Haemolytic Anaemia |
6.5% |
| Renal Failure Acute |
6.5% |
| Respiratory Failure |
6.5% |
| Convulsion |
3.2% |
| Dyskinesia |
3.2% |
| Gastrointestinal Necrosis |
3.2% |
| Haemoglobin Decreased |
3.2% |
| Hepatic Function Abnormal |
3.2% |
| Hypertriglyceridaemia |
3.2% |
| Jaundice |
3.2% |
| Neutrophil Count Increased |
3.2% |
| Oxygen Saturation Decreased |
3.2% |
| Pancreatitis |
3.2% |
| Paroxysmal Arrhythmia |
3.2% |
| Pneumonia |
3.2% |
| Pseudomonas Infection |
3.2% |
|
| Concomitant |
| Prophylaxis |
17.5% |
| Product Used For Unknown Indication |
17.0% |
| Acute Myeloid Leukaemia |
13.2% |
| Acute Lymphocytic Leukaemia |
7.9% |
| Drug Use For Unknown Indication |
7.2% |
| Diffuse Large B-cell Lymphoma |
6.3% |
| Nausea |
3.5% |
| Pyrexia |
3.4% |
| Premedication |
3.3% |
| Hypertension |
3.1% |
| Supplementation Therapy |
2.5% |
| Acute Lymphocytic Leukaemia Recurrent |
2.1% |
| Infection Prophylaxis |
2.0% |
| Pain |
2.0% |
| B-cell Lymphoma |
1.6% |
| Constipation |
1.5% |
| Febrile Neutropenia |
1.5% |
| Chemotherapy |
1.4% |
| Myelodysplastic Syndrome |
1.4% |
| Sedation |
1.4% |
|
| Septic Shock |
18.6% |
| Tumour Lysis Syndrome |
17.6% |
| Sepsis |
6.9% |
| Renal Failure |
5.9% |
| Death |
4.9% |
| Epistaxis |
4.9% |
| Hepatitis B |
4.9% |
| Vomiting |
4.9% |
| Pancreatitis Acute |
3.9% |
| Thrombocytopenia |
3.9% |
| Anaemia |
2.9% |
| Nausea |
2.9% |
| Pneumonia |
2.9% |
| Skin Exfoliation |
2.9% |
| C-reactive Protein Increased |
2.0% |
| Cholecystitis Acute |
2.0% |
| Diarrhoea |
2.0% |
| Gastrointestinal Necrosis |
2.0% |
| Hemiplegia |
2.0% |
| Hepatic Failure |
2.0% |
|
